Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial
<h3>Background</h3> We assessed the efficacy and safety of avelumab, an anti-programmed death ligand 1 (PD-L1) antibody, in patients with previously treated metastatic adrenocortical carcinoma (mACC). <h3>Methods</h3> In this phase 1b expansion cohort, patients with mACC and...
Wedi'i Gadw mewn:
| Prif Awduron: | , , , , , , , , , , , |
|---|---|
| Fformat: | Artigo |
| Iaith: | Saesneg |
| Cyhoeddwyd: |
2018
|
| Mynediad Ar-lein: | https://doi.org/10.1186/s40425-018-0424-9 https://jitc.bmj.com/content/jitc/6/1/111.full.pdf |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|